Current position:News > News > Insights
CD38: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
吉满生物
2024-09-23

June 3, 2024. Sanofi issued a press release stating that its CD38 monoclonal antibody Sarclisa has been approved in the United States as the first anti-CD38 therapy.

Sarclisa is the first anti-CD38 drug to significantly improve progression-free survival in combination with VRd for the treatment of newly diagnosed transplant-eligible multiple myeloma.

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free survival (PFS), compared to standard-of-care in newly diagnosed adult patients not eligible for autologous stem cell transplant (ASCT).

Third indication for Sarclisa, evaluated under FDA Priority Review, underscores Sanofi’s commitment to helping close a critical care gap in multiple myeloma (MM).

Genomeditech launches stable high-expression cell lines and antibody products to help CD38 drug development! Click here to learn more about our CD38 catalog

Latest news
Insights
2026-01-29
PD-1 Agonists: Insights into Their Growing Impact
PD-1 has long been a milestone target in cancer immunotherapy, with PD-1/PD-L1 inhibitors driving major advances in oncology. Now, the same pathway is being explored from the opposite angle: PD-1 agonists for autoimmune diseases. By enhancing immune inhibition, these therapies aim to suppress overactive T cells, addressing conditions such as rheumatoid arthritis, SLE, and primary Sjogren’s syndrome.
Insights
2026-01-22
Will B7-H3 Become the Next Major ADC Target?
The B7-H3 (CD276) ADC field is heating up in 2026. Recent deals—DualityBio & Roche, InnoLake & Ellipses Pharma—highlight global interest and the therapeutic potential of this target.

B7-H3 is overexpressed in multiple solid tumors and contributes to immune evasion. ADCs targeting B7-H3 are showing promising early clinical activity, with several programs advancing into Phase III trials, including YL201, HS-20093, and inatamab deruxtecan. Combination strategies with PD-(L)1 inhibitors are also expanding the potential of this target.
Insights
2025-12-24
IL-5: a key regulator of eosinophilic inflammation
Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.
Current position:News > News > Insights
classify
CD38: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
吉满生物
2024-09-23

June 3, 2024. Sanofi issued a press release stating that its CD38 monoclonal antibody Sarclisa has been approved in the United States as the first anti-CD38 therapy.

Sarclisa is the first anti-CD38 drug to significantly improve progression-free survival in combination with VRd for the treatment of newly diagnosed transplant-eligible multiple myeloma.

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free survival (PFS), compared to standard-of-care in newly diagnosed adult patients not eligible for autologous stem cell transplant (ASCT).

Third indication for Sarclisa, evaluated under FDA Priority Review, underscores Sanofi’s commitment to helping close a critical care gap in multiple myeloma (MM).

Genomeditech launches stable high-expression cell lines and antibody products to help CD38 drug development! Click here to learn more about our CD38 catalog

Message consultation
reset
submit
Message
Message consultation
reset
submit